Gemfibrozil-Induced Polyuria

Ashraf Ahmed; Edmond Okotcha; Abdul-Hussein Saad

doi:10.12890/2021_002546

Ashraf Ahmed
Hamad Medical Corporation, Department of Medicine, Doha, Qatar
Edmond Okotcha
Patient First Medical Center affiliated with Beaumont Hospital, Dearborn, Michigan USA
Abdul-Hussein Saad
Patient First Medical Center affiliated with Beaumont Hospital, Dearborn, Michigan USA

Keywords

Gemfibrozil, anti-hyperlipidaemic, urinary side effects, polyuria

Abstract

Gemfibrozil is a lipid-regulating agent used mainly to treat patients with hypertriglyceridaemia, especially those at risk for acute pancreatitis. Like any other pharmacological agent, gemfibrozil has known adverse effects, mainly gastrointestinal, such as cholelithiasis, gallstones, elevated transaminase, and other non-specific symptoms including dyspepsia, nausea and vomiting. Other reported adverse reactions are dizziness and vertigo, myopathy and rhabdomyolysis, angioedema, urticaria and rash. As far as we knew, gemfibrozil does not have urinary tract adverse reactions. In this report, we present a case of polyuria secondary to gemfibrozil with a score of 9 on the Naranjo scale, and a literature review.

VIEW THE ENTIRE ARTICLE

HTML
PDF

References

Hendrani AD, Adesiyun T, Quispe R, Jones SR, Stone NJ, Blumenthal RS, et al Dyslipidemia management in primary prevention of cardiovascular disease: current guidelines and strategies. World J Cardiol 2016;8(2):201–210. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766270/pdf/WJC-8-201.pdf

Bitzur R, Cohen H, Kamari Y, Harats D. Intolerance to statins: mechanisms and management. Diabetes Care 2013;36(Suppl 2):S325–S330. https://care.diabetesjournals.org/content/diacare/36/Supplement_2/S325.full.pdf

Ito MK. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. Atherosclerosis 2015;242(2):647–656.

Bussière-Côté S, Omlin T, de Càssia Pinheiro E, Weber J-M. Gemfibrozil disrupts the metabolism of circulating lipids in bobwhite quails. Comp Biochem Physiol Toxicol Pharmacol 2016;179:137–143. doi:10.1016/j.cbpc.2015.09.011

Ghosh A, Rangasamy SB, Modi KK, Pahan K. Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis. J Neurochem 2017;141(3):423–435. doi:10.1111/jnc.13987

Ito MK. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. Atherosclerosis 2015;242(2):647–656. doi:10.1016/j.atherosclerosis.2015.06.012

Quintanilla Rodriguez BS, Correa R. Gemfibrozil. Treasure Island (FL): StatPearls Publishing; 2021. https://www.ncbi.nlm.nih.gov/books/NBK545266/?report=printable

Haybar H, Goudarzi M, Mehrzadi S, Aminzadeh A, Khodayar MJ, Kalantar M, et al. Effect of gemfibrozil on cardiotoxicity induced by doxorubicin in male experimental rats. Biomed Pharmacother Biomedecine Pharmacother 2019;109:530–535. doi:10.1016/j.biopha.2018.10.101

Chandra S, Pahan K. Gemfibrozil, a lipid-lowering drug, lowers amyloid plaque pathology and enhances memory in a mouse model of Alzheimer’s disease via peroxisome proliferator-activated receptor ?. J Alzheimers Dis Rep 2019;3(1):149–168. doi:10.3233/ADR-190104

Martín-Navarro JA. Acute renal failure secondary to interstitial acute nephritis and Fanconi syndrome due to metamizole and gemfibrozil. Nefrologia 2016;36(3):321–323.

Adverse drug reaction probability scale (Naranjo) in drug induced liver injury. In: LiverTox: clinical and research information on drug-induced liver injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Accessed 24 March 2021. http://www.ncbi.nlm.nih.gov/books/NBK548069/